Literature DB >> 16520742

Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.

Toshio Uemura1, Tomihisa Kawasaki, Masatoshi Taniguchi, Yumiko Moritani, Kazumi Hayashi, Tetsu Saito, Jun Takasaki, Wataru Uchida, Keiji Miyata.   

Abstract

1 The effects of YM-254890, a specific Galpha(q/11) inhibitor, on platelet functions, thrombus formation under high-shear rate condition and femoral artery thrombosis in cynomolgus monkeys were investigated. 2 YM-254890 concentration dependently inhibited ADP-induced intracellular Ca(2+) elevation, with an IC(50) value of 0.92+/-0.28 microM. 3 P-selectin expression induced by ADP or thrombin receptor agonist peptide (TRAP) was strongly inhibited by YM-254890, with IC(50) values of 0.51+/-0.02 and 0.16+/-0.08 microM, respectively. 4 YM-254890 had no effect on the binding of fibrinogen to purified GPIIb/IIIa, but strongly inhibited binding to TRAP-stimulated washed platelets. 5 YM-254890 completely inhibited platelet shape change induced by ADP, but not that induced by collagen, TRAP, arachidonic acid, U46619 or A23187. 6 YM-254890 attenuated ADP-, collagen-, TRAP-, arachidonic acid- and U46619-induced platelet aggregation with IC(50) values of <1 microM, whereas it had no effect on phorbol 12-myristate 13-acetate-, ristocetin-, thapsigargin- or A23187-induced platelet aggregation. 7 High-shear stress-induced platelet aggregation and platelet-rich thrombus formation on a collagen surface under high-shear flow conditions were concentration dependently inhibited by YM-254890. 8 The antithrombotic effect of YM-254890 was evaluated in a model of cyclic flow reductions in the femoral artery of cynomolgus monkeys. The intravenous bolus injection of YM-254890 dose dependently inhibited recurrent thrombosis without affecting systemic blood pressure or prolonging template bleeding time. 9 YM-254890 is a useful tool for investigating Galpha(q/11)-coupled receptor signaling and the physiological roles of Galpha(q/11).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16520742      PMCID: PMC1617042          DOI: 10.1038/sj.bjp.0706711

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

Review 1.  The role of heterotrimeric G proteins in platelet activation.

Authors:  S Offermanns
Journal:  Biol Chem       Date:  2000 May-Jun       Impact factor: 3.915

2.  YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp. QS3666.

Authors:  Masatoshi Taniguchi; Koji Nagai; Nakako Arao; Tomihisa Kawasaki; Tetsu Saito; Yumiko Moritani; Jun Takasaki; Kazumi Hayashi; Shigeo Fujita; Ken-ichi Suzuki; Shin-ichi Tsukamoto
Journal:  J Antibiot (Tokyo)       Date:  2003-04       Impact factor: 2.649

3.  Pharmacological properties of YM-254890, a specific G(alpha)q/11 inhibitor, on thrombosis and neointima formation in mice.

Authors:  Tomihisa Kawasaki; Masatoshi Taniguchi; Yumiko Moritani; Toshio Uemura; Takeshi Shigenaga; Hajime Takamatsu; Kazumi Hayashi; Jun Takasaki; Tetsu Saito; Koji Nagai
Journal:  Thromb Haemost       Date:  2005-07       Impact factor: 5.249

4.  Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction.

Authors:  A Mathur; M S Robinson; J Cotton; J F Martin; J D Erusalimsky
Journal:  Thromb Haemost       Date:  2001-06       Impact factor: 5.249

5.  Gq-coupled receptor agonists mediate cardiac hypertrophy via the vasculature.

Authors:  Janelle R Keys; Emily A Greene; Walter J Koch; Andrea D Eckhart
Journal:  Hypertension       Date:  2002-11       Impact factor: 10.190

6.  Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist.

Authors:  A Baurand; P Raboisson; M Freund; C Léon; J P Cazenave; J J Bourguignon; C Gachet
Journal:  Eur J Pharmacol       Date:  2001-02-02       Impact factor: 4.432

7.  A new generation of Ca2+ indicators with greatly improved fluorescence properties.

Authors:  G Grynkiewicz; M Poenie; R Y Tsien
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

8.  The roles of P(2X1)and P(2T AC)receptors in ADP-evoked calcium signalling in human platelets.

Authors:  S O Sage; E H Yamoah; J W Heemskerk
Journal:  Cell Calcium       Date:  2000-08       Impact factor: 6.817

Review 9.  Role of inflammatory mediators in thrombogenesis.

Authors:  Ronald J Shebuski; Kenneth S Kilgore
Journal:  J Pharmacol Exp Ther       Date:  2002-03       Impact factor: 4.030

10.  Antithrombotic and thrombolytic efficacy of YM-254890, a G q/11 inhibitor, in a rat model of arterial thrombosis.

Authors:  Tomihisa Kawasaki; Masatoshi Taniguchi; Yumiko Moritani; Kazumi Hayashi; Tetsu Saito; Jun Takasaki; Koji Nagai; Osamu Inagaki; Hisataka Shikama
Journal:  Thromb Haemost       Date:  2003-09       Impact factor: 5.249

View more
  19 in total

Review 1.  State-selective binding peptides for heterotrimeric G-protein subunits: novel tools for investigating G-protein signaling dynamics.

Authors:  Christopher A Johnston; Francis S Willard; J Kevin Ramer; Rainer Blaesius; C Natalia Roques; David P Siderovski
Journal:  Comb Chem High Throughput Screen       Date:  2008-06       Impact factor: 1.339

Review 2.  Platelet activation, and antiplatelet targets and agents: current and novel strategies.

Authors:  Yao-Zu Xiang; Ye Xia; Xiu-Mei Gao; Hong-Cai Shang; Li-Yuan Kang; Bo-Li Zhang
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms.

Authors:  Noritaka Imamachi; Goon Ho Park; Hyosang Lee; David J Anderson; Melvin I Simon; Allan I Basbaum; Sang-Kyou Han
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-29       Impact factor: 11.205

4.  Gq signaling causes glomerular injury by activating TRPC6.

Authors:  Liming Wang; Grant Jirka; Paul B Rosenberg; Anne F Buckley; Jose A Gomez; Timothy A Fields; Michelle P Winn; Robert F Spurney
Journal:  J Clin Invest       Date:  2015-04-06       Impact factor: 14.808

5.  Novel antiplatelet agents in cardiovascular medicine.

Authors:  Rahil Rafeedheen; Kevin P Bliden; Fang Liu; Udaya S Tantry; Paul A Gurbel
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-06

Review 6.  G-protein-coupled receptors signaling pathways in new antiplatelet drug development.

Authors:  Paul A Gurbel; Athan Kuliopulos; Udaya S Tantry
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-01-29       Impact factor: 8.311

7.  Total synthesis and structure-activity relationship studies of a series of selective G protein inhibitors.

Authors:  Xiao-Feng Xiong; Hang Zhang; Christina R Underwood; Kasper Harpsøe; Thomas J Gardella; Mie F Wöldike; Michael Mannstadt; David E Gloriam; Hans Bräuner-Osborne; Kristian Strømgaard
Journal:  Nat Chem       Date:  2016-07-25       Impact factor: 24.427

8.  On the selectivity of the Gαq inhibitor UBO-QIC: A comparison with the Gαi inhibitor pertussis toxin.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2016-03-05       Impact factor: 5.858

9.  Fucoidan is a novel platelet agonist for the C-type lectin-like receptor 2 (CLEC-2).

Authors:  Bhanu Kanth Manne; Todd M Getz; Craig E Hughes; Osama Alshehri; Carol Dangelmaier; Ulhas P Naik; Steve P Watson; Satya P Kunapuli
Journal:  J Biol Chem       Date:  2013-01-22       Impact factor: 5.157

10.  Examination of signalling pathways involved in muscarinic responses in bovine ciliary muscle using YM-254890, an inhibitor of the Gq/11 protein.

Authors:  F Yasui; M Miyazu; A Yoshida; K Naruse; A Takai
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.